Brain Trauma Oncology 13.


Stummer W, Reulen HJ, Meinel T, et al., Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias, Neurosurgery, 2008;62(3):564–76.


14.


Lacroix M, Abi-Said D, Fourney DR, et al., A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival, J Neurosurg, 2001;95(2):190–98.


15.


Walker MD, Alexander E Jr, Hunt WE, et al., Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial, J Neurosurg, 1978;49(3):333–43.


16. 17.


Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 2005;352(10):987–96.


Lee SW, Fraass BA, Marsh LH, et al., Patterns of failure following high-dose 3-D conformal radiotherapy for high- grade astrocytomas: a quantitative dosimetric study, Int J Radiat Oncol Biol Phys, 1999;43(1):79–88.


18. 19. 20. 21.


Fiveash JB, Spencer SA, Role of radiation therapy and radiosurgery in glioblastoma multiforme, Cancer J, 2003;9:222–9.


Stupp R, Hegi ME, Gilbert MR, Chakravarti A, Chemoradiotherapy in malignant glioma: standard of care and future directions, J Clin Oncol, 2007;25(26): 4127–36.


Chi AS, Wen PY, Inhibiting kinases in malignant gliomas, Expert Opin Ther Targets, 2007;11(4):473–96.


Duda DG, Jain RK, Willett CG, Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers, J Clin Oncol, 2007;25(26):4033–42.


22. 23.


Stieber VW, Mehta MP, Advances in radiation therapy for brain tumours, Neurol Clin, 2007;25(4):1005–33.


Tsao MN, Mehta MP, Whelan TJ, et al., The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma, Int J Radiat Oncol Biol Phys, 2005;63(1): 47–55.


24.


Combs SE, Thilmann C, Edler L, et al., Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution, J Clin Oncol, 2005;23(34):8863–9.


25.


Stupp R, Hegi ME, Mason WP, et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, 2009;10(5):459–66.


26.


Brandes AA, Tosoni A, Cavallo G, et al., Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study, J Clin Oncol, 2006;24(29):4746–53.


27.


Brandes A, Tosoni A, Cavallo G, et al., Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO), Br J Cancer, 2006;95(9):1155–60.


28.


Wick A, Felsberg J, Steinbach JP, et al., Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma, J Clin Oncol, 2007;25(22):3357–61.


29.


Perry JR, Belanger K, Mason WP, et al., Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study, J Clin Oncol, 2010;28(12):2051–7.


30.


Tolcher AW, Gerson SL, Denis L, et al., Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules, Br J Cancer, 2003;88(7):1004–11.


31.


Broniscer A, Gururangan S, MacDonald TJ, et al., Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumours: a pediatric brain tumour consortium report, Clin Cancer Res, 2007;13(22 Pt 1):6712–18.


32. 62 Quinn JA, Jiang SX, Reardon DA, et al., Phase 1 trial of 39.


temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma, Cancer, 2009;115(13):2964–70.


33.


Quinn JA, Jiang SX, Reardon DA, et al., Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma, J Clin Oncol, 2009;27(8):1262–7.


34.


Westphal M, Hilt DC, Bortey E, et al., A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neuro Oncol, 2003;5(2):79–88.


35. 36.


Brandes AA, Ermani M, Basso U, et al., Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study, Ann Oncol, 2001;12(2): 255–7.


Yung W, Albright R, Olson J, et al., A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, Br J Cancer, 2000;83(5):588–93.


37. 38.


Wong ET, Hess KR, Gleason MJ, et al., Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials, J Clin Oncol, 1999;17(8): 2572–8.


Brem H, Piantadosi S, Burger PC, et al., Placebo- controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent malignant gliomas: The Polymer-brain Tumour Treatment Group, Lancet, 1999;345:1008–12.


Kreisl TN, Kim L, Moore K, et al., Phase II trial of single- agent bevacizumab followed by bevacizumab plus irinotecan at tumour progression in recurrent glioblastoma, J Clin Oncol, 2009;27(5):740–45.


40. 41.


Friedman HS, Prados MD, Wen PY, et al., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, 2009;27(28):4733–40.


Quant EC, Norden AD, Drappatz J, et al., Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab, Neuro Oncol, 2009;11(5):550–55.


42.


Wick W, Hartmann C, Engel C, et al., NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide, J Clin Oncol, 2009;27(35): 5874–80.


43. 44.


van den Bent MJ, Anaplastic oligodendroglioma and oligoastrocytoma, Neurol Clin, 2007;25(4):1089–1109.


Jenkins RB, Blair H, Ballman KV, et al., A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma, Cancer Res, 2006;66(20):9852–61.


45.


Cairncross JG, Ueki K, Zlatescu MC, et al., Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas, J Natl Cancer Inst, 1998;90(19):1473–9.


46.


Cairncross G, Berkey B, Shaw E, et al., Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402, J Clin Oncol, 2006;24(18): 2707–14.


47.


van den Bent MJ, Carpentier AF, Brandes AA, et al., Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial, J Clin Oncol, 2006;24(18):2715–22.


48.


Van Meir EG HC, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma, CA Cancer J Clin, 2010; 60(3):166–93.


49.


Jain RK, di Tomaso E, Duda DG, et al., Angiogenesis in brain tumours, Nat Rev Neurosci, 2007;8(8):610–22.


50. Folkman J, Tumour angiogenesis: therapeutic implications, N Engl J Med, 1971;285(21):1182–6.


51. Folkman J, Angiogenesis, Ann Rev Med, 2006;57:1–18. 52.


Norden AD, Drappatz J, Wen PY, Antiangiogenic therapy in malignant gliomas, Curr Opin Oncol, 2008;20(6):652–61.


75. 67. 68. 57. 58. 53. 54. 55. 56.


Vredenburgh JJ, Desjardins A, Herndon JE II, et al., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme, J Clin Oncol, 2007;25(30):4722–9.


Vredenburgh JJ, Desjardins A, Herndon JE II, et al., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin Cancer Res, 2007;13(4):1253–9.


Desjardins A, Reardon DA, Herndon JE II, et al., Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas, Clin Cancer Res, 2008;14(21):7068–73.


Lai A, Filka E, McGibbon B, et al., Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability, Int J Radiat Oncol Biol Phys, 2008;71(5):1372–80.


Holash J, Davis S, Papadopoulos N, et al., VEGF-Trap: a VEGF blocker with potent antitumour effects, Proc Natl Acad Sci U S A, 2002;99(17):11393–8.


Batchelor TT, Duda DG, di Tomaso E, et al., Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma, J Clin Oncol, 2010;28(17):2817–23


59. 60. 61. 62. 63. 64. 65.


Norden AD, Drappatz J, Wen PY, Antiangiogenic therapies for high-grade glioma, Nat Rev Neurol, 2009;5(11):610–20.


Bergers G, Hanahan D. Modes of resistance to anti- angiogenic therapy, Nat Rev Cancer, 2008;8(8):592–603.


Ellis LM, Hicklin DJ, Pathways mediating resistance to vascular endothelial growth factor-targeted therapy, Clin Cancer Res, 2008;14(20):6371–5.


Holash J, Maisonpierre P, Compton D, et al., Vessel cooption, regression, and growth in tumours mediated by angiopoietins and VEGF, Science, 1999;284(5422): 1994–8.


Lamszus K, Kunkel P, Westphal M, Invasion as limitation to anti-angiogenic glioma therapy, Acta Neurochir Suppl, 2003;88:169–77.


Rubenstein JL, Kim J, Ozawa T, et al., Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption, Neoplasia, 2000;2(4):306–14.


Paez-Ribes M, Allen E, Hudock J, et al., Antiangiogenic therapy elicits malignant progression of tumours to increased local invasion and distant metastasis, Cancer Cell, 2009;15(3):220–31.


66.


Norden AD, Young GS, Setayesh K, et al., Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence, Neurology, 2008;70(10):779–87.


Iwamoto FM, Abrey LE, Beal K, et al., Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma, Neurology, 2009;73(15): 1200–1206.


Zuniga RM, Torcuator R, Jain R, et al., Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan, J Neurooncol, 2009;91(3): 329–36.


69. 70.


Gerstner ER, Chen PJ, Wen PY, et al., Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib, Neuro Oncol, 2010;12(5):466–72.


de Groot J, Fuller G, Kumar AJ, et al., Tumour invasion after treatment of glioblastoma with


bevacizumab:radiographic and pathologic correlation in humans and mice, Neuro Oncol, 2010;12(3):233–42.


71.


Wen PY, Macdonald DR, Reardon DA, et al., Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group, J Clin Oncol, 2010;28(11):1963–72.


72.


Batchelor T, Sorensen A, di Tomaso E, et al., AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumour Vasculature and Alleviates Edema in Glioblastoma Patients, Cancer Cell, 2007;11(1):83–95.


73. 74.


Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis, Nat Rev Cancer, 2008;8(8):604–17.


Stupp R, Goldbrunner R, Neyns B, et al., Mature results of a phase I/IIa trial of the integrin inhibitor cilengitide (EMD121974) added to standard concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma, Neuro Oncol, 2007;9(4):517. Maher E, Furnari F, Bachoo R, et al., Malignant glioma:


US NEUROLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108